We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 16, 2021

Two-Dose mRNA COVID-19 Vaccine Effectiveness in Immunocompromised Adults

MMWR. Morbidity and Mortality Weekly Report

 

Additional Info

Disclosure statements are available on the authors' profiles:

MMWR. Morbidity and Mortality Weekly Report
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021
MMWR Morb. Mortal. Wkly. Rep. 2021 Nov 05;70(44)1553-1559, PJ Embi, ME Levy, AL Naleway, P Patel, M Gaglani, K Natarajan, K Dascomb, TC Ong, NP Klein, IC Liao, SJ Grannis, J Han, E Stenehjem, MM Dunne, N Lewis, SA Irving, S Rao, C McEvoy, CH Bozio, K Murthy, BE Dixon, N Grisel, DH Yang, K Goddard, AB Kharbanda, S Reynolds, C Raiyani, WF Fadel, J Arndorfer, EA Rowley, B Fireman, J Ferdinands, NR Valvi, SW Ball, O Zerbo, EP Griggs, PK Mitchell, RM Porter, SA Kiduko, L Blanton, Y Zhuang, A Steffens, SE Reese, N Olson, J Williams, M Dickerson, M McMorrow, SJ Schrag, JR Verani, AM Fry, E Azziz-Baumgartner, MA Barron, MG Thompson, MB DeSilva

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.